Oncogenetic landscape and clinical impact of IDH1 and IDH2 mutations in T-ALL

IDH1 and IDH2 mutations (IDH1/2(Mut)) are recognized as recurrent genetic alterations in acute myeloid leukemia (AML) and associated with both clinical impact and therapeutic opportunity due to the recent development of specific IDH1/2(Mut) inhibitors. In T-cell acute lymphoblastic leukemia (T-ALL),...

Descripción completa

Detalles Bibliográficos
Autores principales: Simonin, Mathieu, Schmidt, Aline, Bontoux, Christophe, Dourthe, Marie-Émilie, Lengliné, Etienne, Andrieu, Guillaume P., Lhermitte, Ludovic, Graux, Carlos, Grardel, Nathalie, Cayuela, Jean-Michel, Huguet, Françoise, Arnoux, Isabelle, Ducassou, Stéphane, Macintyre, Elizabeth, Gandemer, Virginie, Dombret, Hervé, Petit, Arnaud, Ifrah, Norbert, Baruchel, André, Boissel, Nicolas, Asnafi, Vahid
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Rapid Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8091755/
https://www.ncbi.nlm.nih.gov/pubmed/33941203
http://dx.doi.org/10.1186/s13045-021-01068-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8091755/
https://www.ncbi.nlm.nih.gov/pubmed/33941203
http://dx.doi.org/10.1186/s13045-021-01068-4

Ejemplares similares